235 Studies Now Enrolling
Menu
Search
Status
Medical Condition
- Show all (1752)
- Addiction (19)
- Allergy, Asthma, & Immunology (13)
- All of Us Research Program - NIH (1)
- Autoimmune Disorders (29)
- Blood Disorders (33)
- Bone & Muscle (10)
- Cancer
(564)
- Bladder Cancer (13)
- Brain Cancer (12)
- Breast Cancer (60)
- Gastrointestinal (10)
- Gynecologic Cancer (30)
- Head and Neck Cancer (4)
- Kidney Cancer (7)
- Leukemia (64)
- Liver Cancer (4)
- (-) Lung Cancer (57)
- Lymphoma (24)
- Multiple Myeloma (24)
- Pancreatic Cancer (6)
- Prostate Cancer (25)
- (-) Sarcoma (23)
- Skin Cancer (26)
- Solid Tumors (36)
- Thyroid Cancer (1)
- Uveal Melanoma (7)
- Child Development (4)
- COVID-19 (Coronavirus) (36)
- Critical Illness (1)
- Diabetes (21)
- Ear, Nose and Throat (12)
- Endocrine & Metabolic Disease (12)
- Eye (7)
- Gastrointestinal and Digestive Diseases (26)
- Hair and Skin Disorders (3)
- Headaches (5)
- Healthy Volunteers (187)
- Heart Disease (130)
- Infectious Disease (49)
- Insomnia (2)
- Kidney Disease (12)
- Liver Disease (53)
- Lung Disease (31)
- Meniere's Disease (1)
- Neurological Disorders (165)
- Nutrition (5)
- Obesity (10)
- Obstetrics & Gynecology (55)
- Pain Management (1)
- Pediatrics (103)
- Psychiatric Disorders (67)
- Rehabilitation (9)
- Stroke (7)
- Surgery (7)
- Transplant (48)
- Urology (4)
- Vascular Conditions (10)
Displaying 1 - 124 of 124
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study is to understand more about the combination of amivantamab and lazertinib in non-small cell lung cancer (NSCLC) who have a specific mutation in the EGFR (epidermal growth factor receptor) gene and have not had prior treatment for their disease. The Food and Drug Administration (FDA) has not approved the combination of amivantamab…
Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Closed
This study is being done to test the orally administered study drug, CA-4948 alone, in combination with ibrutinib, or ibrutinib alone in adult patients ages 18 and over diagnosed with relapsed or refractory (RR) Primary Central Nervous System Lymphoma (PCNSL). This study will take place at multiple centers globally. The study drug, CA-4948, is thought to…
Condition: Neurological Disorders / Brain Tumors
Investigator: Tony J. Wang, MD
Status: Closed
The purpose of this study is to find out if performing Magnetic Resonance Image (MRI) scans of your brain with adaptive planning during your radiation treatment of your high-grade glioma will help determine how sensitive the images collected of the brain are at detecting the response of the tumor to the cancer treatment. In this study, four or seven MRI…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study is to evaluate the safety and effectiveness of an experimental drug, BDTX1535, which is not yet approved by the United States Food and Drug Administration (FDA), intreating patients with advanced solid tumors with changes in a protein named epidermal growth factor receptor (EGFR), which may or may not help your condition during…
Condition: Cancer / Lung Cancer
Investigator: Benjamin Herzberg, MD
Status: Closed
The purpose this study to learn more about if a medication called durvalumab will work and be safe for the treatment of non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic) with certain genetic changes when given in combination with tremelimumab and standard chemotherapy. Additionally, this study is being done to better…
Condition: Neurological Disorders / Brain Tumors
Investigator: Mikhail Doubrovin, MD
Status: Closed
The purpose of the study is to evaluate the safety of Lutathera alone in patients with recurrent glioblastoma and the combination of Lutathera with radiotherapy with temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GB) and to establish the appropriate dose of this combination. Lutathera is a radioligand therapy, which is a targeted…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
This study will compare the effectiveness of osimertinib alone to the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene for the epidermal growth factor receptor (EGFR). Osimertinib alone is the usual treatment for metastatic EGFR-mutant lung cancer. This…
Condition: Neurological Disorders / Brain Tumors
Investigator: Stergios Zacharoulis, MD
Status: Closed
Children and young adults with diffuse midline glioma will be treated with Focused Ultrasound (FUS) with DEFINITY microbubbles and neuro-navigator-controlled sonication. The overall goal of this study is to see if the study treatment plan will improve the outcome of participants with diffuse midline glioma, for which no known cure exists, and determine…
Condition: Cancer / Sarcoma
Investigator: Prabhjot Mundi, MD
Status: Closed
You are being asked to participate in this study because you have been diagnosed with a progressive desmoid tumor. The purpose of this study is to see if the study drug, called AL102 (referred to from now on as the study drug), is safe and effective in people with progressive desmoid tumors. The study will also look at how your body responds to the study…
Condition: Neurological Disorders / Brain Tumors
Investigator: Mary Welch, MD
Status: Closed
The purpose of this study is to test good and bad effects of these two different drugs against meningioma tumors with altered genes. Today, therapy for meningioma is the same for all patients and is not based on tumor genetic testing. This trial is trying to see if tumor genetic testing would be helpful at guiding treatment in patients with meningioma.…
Condition: Cancer / Lung Cancer
Investigator: Alicia Matthews
Status: Closed
We are conducting a survey to gather feedback about lung cancer patients experience with treatment and the challenges you faced. Your insights can help shape better care for future patients and explore how technology can be of help! The survey takes 30-40 minutes, and eligible participants who complete it will receive a gift card. Interested in…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
This is a research study evaluating a new investigational drug, called CLN-081. CLN-081 is a type of drug called a tyrosine kinase inhibitor. It targets a mutation in the tumor cell called EGFR exon 20 insertion with the goal to slow down or stop cancer cell growth. It is taken orally (by mouth). There are several different parts to this study, each with…
Condition: Neurological Disorders / Brain Tumors
Investigator: Gurcharanjeet Kaur, MD
Status: Closed
The purpose of this study is to find out if REC-2282, an investigational new drug, is an effective and safe treatment in patients with progressive NF2 mutated meningiomas who have either NF2 disease-related meningioma or recurrent sporadic meningiomas that have NF2 mutation. Investigational new drug means a drug that has not been approved as a marketed…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study to learn more about whether the study drug osimertinib (TAGRISSOTM) is more effective than placebo in participants with epidermal growth factor receptor (EGFR) mutated stage IA2 or IA3 Non-Small Cell Lung Cancer (NSCLC) after complete surgical removal of the tumor. Stages IA2 and IA3 refer to tumor size. A placebo is an inactive…
Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Closed
The purpose of this study is to see how safe and effective Safusidenib erbumine, the study drug, is in treating brain glioma and to find the recommended dose of the study drug for clinical studies. Safusidenib is not Food and Drug Administration (FDA) approved.
Condition: Cancer / Lung Cancer
Investigator: Benjamin Herzberg, MD
Status: Closed
The purpose of this study is to assess the benefits and risks of the study drug, adagrasib, when given either by itself or with another drug, nivolumab, to participants with non-small cell lung cancer and a specific cancer mutation, called KRAS G12C, and whether the study drug or the combination may treat or shrink tumors when given before cancer surgery.…
Condition: Cancer / Lung Cancer
Investigator: Stephanie Smith-Marrone, MD
Status: Closed
The purpose of this study is to compare the drugs ramucirumab and pembrolizumab to standard-of-care treatment in patients whose lung cancer has progressed on immunotherapy. The study doctors hope to learn if the drug combination will help patients with stage IV or recurrent non-small cell lung cancer (NSCLC) live longer. The study is set up to find out if…
Condition: Cancer / Lung Cancer
Investigator: Simon Cheng, MD, PhD
Status: Closed
We are doing this study because we want to find out if MRI brain scans alone is better or worse than MRI brain scans plus preventative brain radiation for patients with small lung cancer. The usual approach for patients with small cell lung cancer is prophylactic cranial irradiation. If you decide to take part in this study, you will either receive PCI for…
Condition: Neurological Disorders / Brain Tumors
Investigator: Mary Welch, MD
Status: Closed
The purpose of this study is to evaluate how safe the investigational drug, DSP-0390, is at different doses and to identify a recommended dose that is safe for further study. Investigational means that the study drug is currently being tested and has not been approved for use alone or in combination with any drug by the U.S. Food and Drug Administration (…
Condition: Neurological Disorders / Brain Tumors
Investigator: Brian Gill, MD
Status: Closed
The purpose of this study is to see how safe the study medicine, IGV-001 plus standard of care (SOC), is and to compare IGV-001 with placebo see if it works in slowing glioblastoma multiforme (GBM) tumor regrowth. SOC refers to the usual medicine(s) or procedures used to treat your cancer. A placebo looks like the study medicine but does not contain any…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study is to see whether the medication osimertinib (TAGRISSOTM) alone or when used in combination with chemotherapy is more effective than chemotherapy alone for the treatment of early stage Non-Small Cell Lung Cancer prior to surgery. Osimertinib is an EGFR TKI therapy that targets EGFR mutations. When a tumor is found to have this type…
Condition: Cancer / Sarcoma
Investigator: Shaheer Khan, DO
Status: Closed
The purpose of this study is to test the good and bad effects of the drugs called belinostat and SGI-110 (guadecitabine). These drugs could shrink your cancer, but they could also cause side effects. The study doctors hope to learn if the study drugs will shrink the cancer more often than observed with other standard treatment options. We dont know if…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study is to compare the usual treatment for Non-Small Cell Lung Cancer (osimertinib) to a combination therapy (osimertinib plus ramucirumab). The combination therapy arm is testing if ramucirumab can help osimertinib control the abnormal EGRG protein for a longer time and keep the disease inactive longer. EGRF protein typically helps the…
Condition: Cancer / Sarcoma
Investigator: Prabhjot Mundi, MD
Status: Closed
The purpose of this study is to evaluate the effectiveness and safety of an investigational drug, unesbulin. This investigational drug is being studied in unresectable or metastatic, relapsed, or refractory leiomyosarcoma along with Dacarbazine. Dacarbazine is a drug that is FDA-approved for the treatment of other types of cancer and recommended by the…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study is to assess the effects, good or bad, of atezolizumab and tiragolumab given with or without chemotherapy (in this study, chemotherapy will be a combination of either paclitaxel with carboplatin, pemetrexed with carboplatin or cisplatin, or gemcitabine with carboplatin or cisplatin) on patients who are able to have surgery to…
Condition: Cancer / Lung Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of the study is to see whether tomivosertib in combination with pembrolizumab treatment slows down the growth of cancers. The study drug, tomivosertib, works by inhibiting the activity of proteins in a pathway that allows tumor cells to grow and go unnoticed by your immune system. This study will evaluate the safety and antitumor activity of…
Condition: Cancer / Sarcoma
Investigator: Shaheer Khan, DO
Status: Closed
The study drug, CFT8634, is an investigational therapy that has been shown in animal studies to help break down the BRD9 protein, an important protein in the body that helps SMARCB-null tumors, such as your own, to grow. CFT8634 is able to do so by using the body's own protein-recycling equipment. (In short, your cells are capable of breaking down…
Condition: Cancer / Sarcoma
Investigator: Prabhjot Mundi, MD
Status: Closed
The purpose of this research study is to determine the effectiveness and safety of envafolimab, an experimental drug that is not approved for use, when given alone or in combination with ipilimumab to stimulate your immune system to attack cancer cells. Envafolimab is an experimental (investigational) cancer drug that overrides the PD-1/PD-L1 checkpoint,…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study is to gain a better understanding of why some patients with non-small cell lung cancer and an epidermal growth factor receptor (EGFR-sensitizing mutation, fail first-line treatment with the drug osermitinib. Additionally, the purpose is to explore different drug therapies for patients whose cancer has progressed (gotten worse)…
Condition: Cancer / Sarcoma
Investigator: Prabhjot Mundi, MD
Status: Closed
The experimental drug called INBRX 109 has been developed as a treatment for unresectable or metastatic conventional chondrosarcoma. The purpose of this study is to learn about the effects of the study drug, INBRX-109 on you, your immune system, and your cancer. This study is being done to understand if INBRX-109 is effective against your chondrosarcoma and…
Condition: Cancer / Sarcoma
Investigator: Benjamin Izar, MD
Status: Closed
The purpose of this study is to evaluate the effectiveness of a new investigational drug, ATX-101, for the treatment of dedifferentiated liposarcoma and leiomyosarcoma. ATX-101 is an intravenous (IV) drug which blocks the interaction of a protein called PCNA with a number of stress response proteins. These interactions are thought to be important for cancer…
Condition: Cancer / Sarcoma
Investigator: Prabhjot Mundi, MD
Status: Closed
The purpose of this study is to learn about the safety, tolerability, and effectiveness of an investigational drug called milademetan as compared to the use of trabectedin. In this study, subjects will be randomly assigned (like flipping a coin) to receive one of two study drugs: milademetan or trabectedin. This is an open-label study, meaning you will know…
Condition: Neurological Disorders / Brain Tumors
Investigator: James Hinkley Garvin Jr, MD
Status: Closed
The purpose of this study is to find the best dose of a drug called MTX110 and a contrast agent called gadolinium that can be given safely in children with newly diagnosed diffuse midline gliomas, which is a kind of brain tumor. All patients enrolled in the study will receive infusion of MTX110 and Gadolinium delivered with a pump directly into the tumor…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study is to see if amivantamab in combination with administration of standard of care chemotherapy (carboplatin and pemetrexed) is safe and useful for treating patients with Non-Small Cell Lung Cancer (NSCLC), specifically in patients with a gene abnormality called EGFR Exon 20 insertions. There are two study arms for this trial.…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study is to see if the study drug, JNJ-61186372, is safe and useful for treating patients with advanced, metastatic, non-small cell lung cancer (NSCLC). There are 2 parts of this study. The first part is to determine the dose of JNJ-61186372 that is safe to give to patients with non-small cell lung cancer. The second part of the study is…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
This study is aimed at finding patients who have small amounts of cancer DNA in their blood (called circulating tumor DNA or ctDNA) after surgery. This may indicate that you have minimal residual disease (MRD), meaning that even after surgery, there are still some remaining cancer cells releasing cancer DNA into your bloodstream. MRD after surgery may mean…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this research study is to find out if a drug called capmatinib is safe and effective (can help people) in people who have non-small cell lung cancer (NSCLC) who are also eligible for surgery. Capmatinib is an oral drug that targets particular processes, which may not be working properly in the cancer cells (dysregulation) in the body. Prior…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study is to see if lazertinib and JNJ-61186372 are safe and useful for treating patients with a type of lung cancer called advanced non-small cell lung cancer (NSCLC) as well as looking at the effects that lazertinib and JNJ-61186372 have when taken together. Lazertinib is taken orally and JNJ-61186372 is an intravenous drug. Lazertinib…
Condition: Cancer / Sarcoma
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to: 1. Compare treatment with chemotherapy (paclitaxel) alone to using a combination of nivolumab plus chemotherapy (paclitaxel) treatment in patients with angiosarcoma who have not been treated with paclitaxel chemotherapy alone. 2. Evaluate the effect of nivolumab in combination with cabozantinib on angiosarcoma (cancer) in…
Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this study is to test the study drug, BI 907828 for safety, effectiveness, and side effects when compared to receiving the standard treatment, doxorubicin, in subjects with dedifferentiated liposarcoma (DDLPS). BI 907828 has proven to minimize a critical protein interaction between MDM2 and p53, two proteins in your body, which when their…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this research study is to see if the combination of medications approved for the treatment of glioblastoma, together with the study drug, selinexor (also known as XPOVIO), has any effects on your cancer. Selinexor works by trapping tumor suppressor proteins within the cell nucleus. This is expected to cause the cancer cells to die or stop…
A Study of PTC596 in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)
Condition: Cancer / Sarcoma
Investigator: Matthew Ingham, MD
Status: Closed
The purpose of this study is to evaluate the effectiveness of a new investigational drug, PTC596, used in combination with dacarbazine, for the treatment of locally recurrent, unresectable, or metastatic relapsed/refractory leiomyosarcoma, a type of soft tissue sarcoma. The purpose of this study is to evaluate whether adding PTC596 to dacarbazine is safe…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
This study is being done to evaluate the safety and usefulness of the study drug, AG-881, as compared to placebo (a medically inactive substance) in residual or recurrent non-enhancing Grade 2 glioma (a type of brain cancer) that has a mutation in the IDH1 or IDH2 metabolic enzyme (a substance produced by the body to assist in breaking down chemicals).…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this research study is to test how safe and how well an investigational drug known as ONC201 works in treating high grade glioma (a type of brain cancer). The FDA (the U.S. Food and Drug Administration) has not approved ONC201 as a treatment for this condition.
Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this study is to find out if an investigational drug, called ADP-A2M4, is safe and how well it works in attacking Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (MRCLS) cancer cells. The study involves taking certain types of immune cells from the blood, called T cells, and changing them in a laboratory before putting them back into the…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this research study is to see how effective durvalumab andtremelimumab is in patients with early stage non-small cell lung cancer (NSCLC). A a special blood test will be done to see if subjects have circulating tumor DNA (ctDNA) in their blood. ctDNA are pieces of genetic material shed from the tumor cells that can be detected in the blood,…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this study is to measure how well and how safe eflornithine is in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has come back after radiation and chemotherapy. Safety and how well you can tolerate the drug will be determined on the basis of physical exams, laboratory tests,…
Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this study is to test the safety of a study drug called AMG 232 given with radiation in patients with soft tissue sarcoma (STS) prior to surgery. The AMG 232 is investigational. It has been tested in other cancers but not yet in sarcoma. AMG 232 has not been tested using the dosing schedule in this study and it has not been tested with…
Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
You are being asked to participate in this study because you have been diagnosed with a progressive desmoid tumor. The purpose of this study is to see if the study drug, called AL102 (referred to from now on as the study drug), is safe and effective in people with progressive desmoid tumors. The study will also look at how your body responds to the study…
Condition: Cancer / Lung Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to test whether local radiotherapy combined with Ipilimumab is safe. The study will try to find out if it can help patients with metastatic non-small cell lung cancer better than treatment with Ipilimumab and Nivolumab alone.
Condition: Cancer / Lung Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
The purpose of this study is to evaluate the combination of MEDI4736 and tremelimumab in treating non-small cell lung cancer. This study will look to see whether MEDI4736 combined with tremelimumab or MEDI4736 alone are more effective than standard of care chemotherapy in treating lung cancer and to collect information on the safety of these drugs. Both…
Condition: Cancer / Lung Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to find if adding the study drug, nivolumab (also known as OPVIDO), will limit lung cancer from growing back in patients with early stage non-small cell lung cancer. Nivolumab is a drug that may turn on the body's immune system to attack any cancer cells that may remain after surgery. The addition of nivolumab may help…
Condition: Neurological Disorders / Brain Tumors
Investigator: Angela Lignelli-Dipple, MD
Status: Closed
The purpose of this research study is to test whether the advanced perfusion MRI done prior to starting Bevacizumab and a few weeks after starting Bevacizumab can determine your response to the treatment better than the standard MRI performed at typical time points. The researchers want to see if this type of advanced MRI is better or the same as what is…
Condition: Cancer / Lung Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to determine the amount (dose) of telaglenastat that is safe and tolerable when given together with the recommended treatment regimen of pembrolizumab, carboplatin, and pemetrexed and to determine if the combination of standard drugs with telaglenastat is more active against non-small cell lung cancer (NSCLC) than the standard…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this research study is to see if Selinexor (KPT-330) has any effects against glioblastoma, a type of brain cancer. The study will be conducted at 3-5 sites in the United States and Europe and plan to enroll 30 patients with brain cancer. Patients will be screened prior to study participation. If their brain tumor is evaluated to require…
Condition: Neurological Disorders / Brain Tumors
Investigator: Teri Kreisl, MD
Status: Closed
The purpose of this study is to find out what effects, good or bad, the experimental device, NovoTTF-100A has on patients with meningioma. This study is being done because currently there are no proveneffective medical treatments for a progressive meningioma that has failed surgery and/or radiation. The NovoTTF-100A System is a portable medical device. It…
Condition: Cancer / Sarcoma
Investigator: Matthew Ingham, MD
Status: Closed
The purpose of this study is to learn about the effects, safety, and proper dosage of tazemetostat in combination with doxorubicin for the treatment of soft tissue sarcoma. Doxorubicin is a common therapy for soft tissue sarcoma, but is not FDA approved in combination with tazemetostat. This study treatment combination may suppress or prevent tumor growth…
Condition: Cancer / Lung Cancer
Investigator: Craig Blinderman, MD, MA
Status: Closed
Research has shown that early involvement of a team of clinicians that specialize in lessening (or palliating) many of these distressing physical and emotional symptoms and in helping patients and their family cope with a serious illness improves patients and their loved ones experience with their cancer. This team is called palliative care, and consists of…
Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Closed
The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of an investigational drug called nivolumab (also known as BMS-936558). Nivolumab is an antibody (a type of human protein) that is being tested to see if it will allow the body's immune system to work against tumor cells.
Condition: Cancer / Lung Cancer
Investigator: Adrian Sacher
Status: Closed
This study is for adults who have non-small cell lung cancer and have had surgery to remove their lung tumor. People who have lung cancer and undergo surgery still have a significant risk of their cancer returning outside of the lung. The purpose of this study is to determine if a new type of immune-based therapy can increase your chance of being cured.…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this study is to look at the effects of an investigational anti-cancer drug (BGB-290) in combination with radiation therapy and/or temozolomide in patients with newly diagnosed or recurring glioblastoma. BGB-290 is expected to work by preventing cancer cells from repairing their damaged genes, causing the progression of cancer to slow down.
Condition: Cancer / Lung Cancer
Investigator: Tony J. Wang, MD
Status: Closed
The purpose of this study is to compare any good and bad effects of avoiding the hippocampus during whole brain radiation to the usual whole-brain radiation. The hippocampus is part of the brain that is important for memory. Avoiding the hippocampus during whole-brain radiation could decrease the chance of side effects on memory and thinking. It also is…
Condition: Cancer / Lung Cancer
Investigator: Sewanti Limaye, MD
Status: Closed
The FLAURA Study is a new clinical research study underway in NSCLC and we are looking for people who would like to join. This study will examine an investigational drug, called AZD9291, and compare it tostandard, approved drugs that are already used to treat lung cancer. These drugs are called gefitinib and erlotinib. When we talk about investigational, it…
Condition: Cancer / Sarcoma
Investigator: Matthew Ingham, MD
Status: Closed
The researchers hope to study the effectiveness of an investigational drug called AL3818 in people who have metastatic (meaning their disease has spread) or advanced ), specifically alveolar soft partsarcoma (ASPS), leiomyosarcoma (LMS) and synovial sarcoma (SS). The main purpose of the study isto learn the percentage of patients that respond to treatment…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study is to compare the effects of atezolizumab, an immunotherapy drug, with chemotherapy or placebo with chemotherapy in patients with resectable NSCLC to find out which is better. In this study, you will receive treatment before undergoing surgery to remove the tumor.
Condition: Neurological Disorders / Brain Tumors
Investigator: Mary Welch, MD
Status: Closed
The purpose of this study is to investigate a novel treatment regimen for patients with recurrent Glioblastomas (GBM). In this phase 2 trial, the potentially synergistic action of PARP inhibition and anti-angiogenesis on DNA repair and biomarkers of angiogenesis and DNA repair will be evaluated.
Condition: Cancer / Lung Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose is to study the safety and the effect of AB122, AB154, and AB928 in participants with stage IV non-small cell lung cancer. Researchers will study the treatment response of AB122 alone as well as in combination with AB154 and AB928. There are three possible groups a participant can be randomly assigned to. Group 1 will include AB122 alone, Group…
Condition: Neurological Disorders / Brain Tumors
Investigator: Mary Welch, MD
Status: Closed
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness ofan investigational drug to learn whether the study drug works in treating a specific disease.Investigational means that the drug is being studied. In this research study, we are looking to compare the effects, good and bad, of the standard of care…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this study is to find out whether study drug bortezomib with radiation therapy and Temozolomide is safe when given to patients with brain tumors. This study will also evaluate the side effects and see whether the combination of bortezomib with radiation and Temozolomide can be effective in shrinking tumors. Bortezomib is the investigational…
Condition: Cancer / Lung Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
This study is being done to determine if REGN2810 (anti-PD-1) in combination with ipilimumab (anti-CTLA-4) plus initial platinum-based doublet chemotherapy, or REGN2810 in combination with ipilimumab will prolong how long you live without your disease progressing compared to the standard of care pembrolizumab (anti-PD-1) monotherapy treatment. Neither…
A study for patients with recurrent glioblastoma or anaplastic astrocytoma using study drug Toca 511
Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Closed
This is a research study to test the effectiveness of Toca 511/Toca FC, an experimental drug, for treatment of recurring brain tumors compared to current standard of care. The study will enroll 370 subjects age 18-85 years who choose to undergo removal of the tumor a second time. At the time of surgery patients will be randomly assigned in a 1:1 ratio to…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
This study will investigate the safety and effectiveness of the study drug SGI-110 in combination with two immunotherapy drugs named durvalumab and tremelimumab in patients with small cell lung cancer who have progressed on other treatments. SGI-110 is a form of chemotherapy known as a "hypomethylating agent" and may help the immunotherapy work…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
New data from the study of ABT-414 and ABBV-221 in patients with recurrent glioblastoma multiforme (GBM) have shown several examples where it seems evidence of disease progression (cancer that continues to grow and spread) was seen in MRI images, but examination of surgically removed tissue under the microscope did not agree with the MRI.
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors (Non-small Cell Lung Cancer)
Condition: Cancer / Lung Cancer
Investigator: Brian Henick, MD
Status: Closed
This research study is being done to test the combination of two new drugs, GSK3359609 and Tremelimumab, in certain cancers. These two drugs are experimental which means they have not been fully tested yet and are not yet approved to treat any disease. There are two parts to this study. Part 1 determines the best dose for the study drugs and part 2 compares…
Condition: Cancer / Lung Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
The purpose of this study is to evaluate the combination of study drug MEDI4736 and tremelimumab in treating advanced non-small cell lung cancer that is resistant to or returned after receiving standard therapies, for which there is no available standard therapies, or for individuals who have declined standard therapies. MEDI4736 and tremelimumab are fully…
Condition: Cancer / Sarcoma
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to establish the safety profile of the study drug HuMax-AXL-ADC in a mixed population of patients with specified solid tumors. HuMax-AXL-ADC binds to a specific antigen called Axl, which is expressed on the tumor cells in the cancer types treated in this trial. When the trial drug binds to the antigen on the tumor cell, the…
Condition: Cancer / Lung Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
The purpose of this study is to determine if the study drug is safe and evaluate whether adjuvant therapy with the study drug will improve overall survival. The study drug is crizotinib (also known as XALKORI). The study will also collect tumor tissue and blood samples for future research.
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of the research study is to see if selinexor has any effects against your cancer and toevaluate the side-effects of selinexor or selinexor in combination with temozolomide (TMZ ). One specific way cancer cells continue to grow is by getting rid of certain proteins called tumor suppressor proteins that would normally cause cancer cells to die.…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
The reason for this study is to find out if the experimental study drug, tesevatinib, is effective as a possible treatment for recurrent glioblastoma. Certain genetic information about your tumor will also be collected, by drawing blood, to help better understand why tesevatinib did or did not work in treating your recurrent glioblastoma. Although…
Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Closed
The purpose of this study is to find out if SL-701 is safe and tolerable for patients with recurrent glioblastoma multiforme (GBM). The study will also look at what effect SL-701 has on patient's brain tumor. SL-701 is a type of anti-cancer vaccine made up of parts 3 different short proteins called "peptides" which are frequently found on…
Condition: Cancer / Lung Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
The purpose of this study screening step is to perform genetic tests on your tumor sample for certain features that investigational targeted agents used in this study are specifically designed to work against. Then the purpose is to assign you to a treatment sub-study that is chosen based on the results (genes and proteins called biomarkers) of this genetic…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
Two different studies have been developed to treat people with anaplastic glioma brain tumors. Onetreatment research study requires a tumor that has the 1p/19q co-deletion tumor marker; the other does not. This treatment research study requires that the subject has a certain kind of tumor, one that is missing part of both chromosomes 1 and 19. These missing…
Condition: Neurological Disorders / Brain Tumors
Investigator: Yazmin Odia, MD
Status: Closed
The purpose of this study is to test whether the new drug, ABT-414, given either alone or with a drug called temozolomide, which is commonly used to treat brain tumors like yours, gives a better outcome than the standard therapy and is safe. The standard therapy can be one of two different regimens, either a drug called lomustine or temozolomide.
Condition: Cancer / Lung Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
The purpose of this study is to look at the effects of treating Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer with the standard treatment or standard treatment in addition to Erlotinib. Subjects will be randomized to one of the two study groups. Subjects will be on the study for up to two years.
Condition: Cancer / Lung Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of an investigational drug called nivolumab on patients with advanced or metastatic non-small cell lung cancer . Nivolumab is an antibody (a type of human protein) that is being tested to see if it will allow the bodys immune system to work against…
Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
The main purpose of this research study is to test different doses of INCB059872 and see which doses are safe and tolerable in participants that have Ewing sarcoma. This study will research the effect that INCB059872 has on your cancer. Researchers will study the way INCB059872 come into and leave your body over time (pharmacokinetics). INCB059872 is a…
Condition: Cancer / Lung Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
This study is being done to test the safety and efficacy of immunotherapy based treatment combinations in patients with metastatic non-small cell lung cancer. Participants will be assigned to one of two groups, Cohort 1 or Cohort 2. Each cohort will be split into Stage 1 and Stage 2 phases.
Condition: Neurological Disorders / Brain Tumors
Investigator: Mary Welch, MD
Status: Closed
The purpose of this study is to: See if taking the study agent, armodafinil, at a dose of 150mg or 250mg, will improve problems with fatigue in patients who have been diagnosed with cancer and are experiencing fatigue. See the effects (good and bad) of taking Armodafinil compared to placebo (an inactive agent) on cancer-related fatigue
Condition: Cancer / Lung Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to determine the doses of RO7121661 that can be administered safely to patients and what the side effects of RO7121661 are. In addition, how RO7121661 affects your body and, in particular, your tumor will be measured. The study also aims to investigate if RO7121661 can slow down or stop the growth of tumors in patients with…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this master study is to test the effectiveness (how well the drug works), safety, and tolerability of an investigational drug called nivolumab (also known as BMS-936558) alone or in combination with standard of care therapies.
Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Closed
The purpose of this study is to find out whether an experimental drug, bevacizumab with temozolomide is safe when given to elderly patients with brain tumors and investigate the side effects of the drug combination and how often they occur. This study will also explore whether bevacizumab and temozolomide can be effective in shrinking tumors when given to…
Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this study is to determine if the study drug toripalimab is safe, to determine future doses to give to patients with cancer, and to measure the amount of toripalimab in the blood. Up to approximately 240 subjects will be enrolled in Part B. The dose given in Part B will be 240 mg. The dose was chosen based upon safety data obtained from…
Condition: Cancer / Lung Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
The purpose of this study is to test the safety of the study drugs and how well your body tolerates it. The study will also test how well the study drugs work to slow down the growth of you tumor or stop your cancer. The study drugs are Cergutuzumab Amunaleukin and Atezolizumab. Atezolizumab is FDA approved for the treatment of patients with metastatic non-…
Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Closed
In this research study, we are looking for Information on how well nivolumab with or without ipilimumab works in combination with TTFields in adult patients with glioblastoma. You will receive the Nivolumab and/or Ipilimumab study treatment until you decide to stop study treatment or your study doctor decides to remove you from the study. This means that…
Condition: Neurological Disorders / Brain Tumors
Investigator: Jeffrey Bruce, MD
Status: Closed
The purpose of this study is to determine the safety of directly injecting a tumor chemotherapy drug called Topotecan and a contrast agent called Gadolinium into malignant brain tumors.
Condition: Neurological Disorders / Brain Tumors
Investigator: Teri Kreisl, MD
Status: Closed
This is a research study to test the effects of VB-111 combined with Bevacizumab versus Bevacizumab alone on glioblastoma . This study will enroll 252 subjects age 18 years and older who have recurrent glioblastoma. All subjects will be randomly assigned in a 1:1 ratio to receive either VB-111 combined with Bevacizumab or Bevacizumab alone. Survival, tumor…
Condition: Cancer / Lung Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
The purpose of this study is to compare the effects of using crizotinib (also known as Xalkori) after completion of surgery, and in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer patients versus placebo. Participants will be randomized to crizotinib or placebo. Participants will take crizotinib/placebo…
Condition: Cancer / Lung Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
The purpose of this study is to see if study drug AZD9291 is effective in treating non-small cell lung cancer (NSCLC) and if so, how it compares with chemotherapy. Only patients with NSCLC that has been confirmed as having the EGFR mutation are eligible to participate. Before patients can participate in the main study a tumor sample will be taken to check…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this research study is to learn about the effects of the study drug, PF-06840003,and to find the best dose for treating research subjects/participants with malignant glioblastoma or anaplastic glioma. PF-068400003 is a new investigational drug. A new investigational drug is one that is currently not approved for sale in this country. PF-…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study is to look at whether the combination of MEDI9447 and osimertinib or MEDI9447 and AZD4635 will improve the outcome in subjects with advanced epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC).
Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Closed
The purpose of this study is to test how well the study drug works in recurrent or isocitratedehydrogenase (IDH) mutant high grade gliomas. The study drug is called Nivolumab. Nivolumab is an antibody (a type of human protein) that is being tested to see if it will allow your own body's immune system to work against tumor cells. Nivolumab is not…
Condition: Cancer / Lung Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to assess the overall safety and efficacy (how well the drug works) of study drug M7824 in the treatment of unresectable, non-small cell lung cancer. Another purpose is to determine whether use of the study drug in combination with chemoradiation (chemotherapy plus radiation therapy) followed by the study drug will result in…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
This study is for patients who are being considered for surgical removal of a specific kind of lung cancer called "non-small lung cancer" (NSCLC), which is a description of the way it looks under a microscope. The purpose of this study is to determine whether adding an investigational treatment called atezolizumab (also called MPDL3280A) to…
Condition: Cancer / Sarcoma
Investigator: Matthew Ingham, MD
Status: Closed
The purpose of this study is to evaluate the effectiveness of preoperative radiation therapy used in combination with the immunostimulatory agent talimogene laherparepvec (T-VEC) to improve outcomes for patients with resectable soft tissue sarcomas, including soft tissue sarcoma (liposarcoma (excluding myxoid liposarcoma), leiomyosarcoma and…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
This is an open-label, Phase II study in patients with metastatic non-small cell lung cancer (NSCLC) whose cancer has gotten worse on an anti-programmed cell death-1/anti-programmed cell death ligand 1 (anti-PD-1/PD-L1) containing therapy. This study consists of a number of treatment cohorts to test the efficacy, safety, and tolerability of multiple…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
This is a two-part research study of an investigational drug called ABBV-321 in subjects with glioblastoma (brain tumor). This study will be conducted in two-parts: 1) Dose Escalation Phase: The purpose of the first part, called a Dose Escalation Phase, is where we will increase the dose of ABBV-321 until we find the highest dose before unmanageable side…
Condition: Neurological Disorders / Brain Tumors
Investigator: Tony J. Wang, MD
Status: Closed
The purpose of this study is to compare any good and bad effects of avoiding the hippocampus during whole-brain radiation plus memantine to using the usual whole-brain radiation plus memantine. The hippocampus is a brain structure that is important for memory. The addition of the hippocampal avoidance technique to the usual whole-brain radiation plus…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
This is a Phase 2b/3 study to compare the effectiveness of the study drug ABT-414 against a placebo. Patients will be randomized to either receive the standard-of-care therapy which consists of radiation therapy/TMZ plus adjuvant TMZ which will be followed by eiter the study drug ABT-414 or a placebo monotherapy.
Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this research study is to learn more about adding the drug ADI-PEG 20 to a standard treatment regimen called gem-tax (the chemotherapy drugs gemcitabine and docetaxel) for subjects with bone and soft tissue sarcoma, and how the addition of ADI-PEG 20 affects the tumors response to treatment and the side effects you experience.
Condition: Cancer / Lung Cancer
Investigator: Sewanti Limaye, MD
Status: Closed
The purpose of this study is to compare the effects, good or bad, of drugs alectinib and crizotnib on patients with lung disease to find out which is better for patients with a special type of non-small cell lung cancer (NSCLC) that is called anaplastic lymphoma kinase (ALK)-positive NSCLC. In this study, participants will receive either alectinib or…
Condition: Cancer / Lung Cancer
Investigator: Brian Henick, MD
Status: Closed
This purpose of this study is to determine whether the tumor cells of lung cancer patients contain changes to the DNA sequence of two proteins found on the cells surface- ALK and EGFR. If the tumor contains changes to the DNA of one of these proteins, the patient may be invited to participate on a trial that will look at drugs which may target tumors that…
Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
The main purpose of this study is to improve treatment of ocular side effects that result from depatuxizumab mafodotin (Depatux-M) use in patients with glioblastoma (GBM). Most people treated with Depatux-M will experience eye side effects. When these side effects are not tolerated, Depatux-M is usually interrupted until symptoms improve and then restarted…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
This research study is testing two potential new drugs called AB928 and AB122. AB928 is an investigational drug that has been shown in animal studies to improve the functioning of the immune system, without causing any immune effects on its own. This research study will help us understand whether AB928, the study drug, can be safely given in combination…
Condition: Cancer / Lung Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
This is a research study to test the effectiveness of pembrolizumab on cancer types having a known relationship to smoking carcinogen exposure. The study will enroll 120 subjects age 18 and above with advanced solid tumor related to smoking exposure. All patients will receive the treatment of pembrolizumab. The study aims to determine if tumor genetics can…
Condition: Cancer / Sarcoma
Investigator: Matthew Ingham, MD
Status: Closed
The purpose of this study is to evaluate the safety and effectiveness of a new combination treatment involving two drugs: selinexor and ixazomib, for the treatment of dedifferentiated liposarcoma, malignant peripheral nerve sheath tumor, alveolar soft part sarcoma and Ewing sarcoma. The primary objective of the study is to determine the maximum tolerated…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
This trial will look at how the study drug will work in combination with traditional chemotherapy at treating extensive-stage small cell lung cancer in the first-line setting. The study will also determine if these drugs cause any side effects compared to traditional chemotherapy alone. The study drug is Durvalumab by itself or with Tremelimumab. Both…
Condition: Neurological Disorders / Brain Tumors
Investigator: Mary Welch, MD
Status: Closed
The purpose of this study is to see if the newly discovered vaccine drug, DSP-7888, will help your immune system to fight against cancer cells that have a protein called WT1. The study will also compare the effectiveness of treatment with DSP-7888 in combination with Bevacizumab versus Bevacizumab alone in patients with glioblastoma (GBM). Bevacizumab has…
Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Closed
This is a research study to test the effectiveness of ICT-107, an experimental drug, with the standard of care (SOC) for treatment of glioblastoma compared to enriched blood cells (PBMC) with the SOC. The study will enroll 400 subjects age 18 years and older with newly diagnosed glioblastoma. Following an initial SOC radiation treatment, patients will be…
Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this study is to determine the safety and effectiveness of the study drug nirogacestat for the treatment of desmoid tumors/aggressive fibromatosis (DT/AF). One group will receive the study medication, the other group will receive a placebo. After the initial phase of the study, participants may elect to participate in another phase of the…
Condition: Cancer / Lung Cancer
Investigator: Bryan Stanifer, MD
Status: Closed
This randomized phase III trial studies how well management of a tobacco treatment intervention works in reducing surgical complications in patients with newly diagnosed lung cancer who smoke cigarettes. Management of a tobacco treatment intervention compares varenicline (a drug that reduces the craving and withdrawal symptoms that occur with abstinence…
Condition: Cancer / Lung Cancer
Investigator: Balazs Halmos, MD
Status: Closed
The purpose of this study is to find out whether the drug, ruxolitinib, is effective, tolerable and safe in combination with two chemotherapy medicines called pemetrexed and cisplatin. The study will test if this combination has beneficial effects in people diagnosed with certain types of non-small cell lung cancer. Only participants with Stage IIIB,…
Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Closed
The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of an investigational drug called nivolumab (also known as BMS-936558). Nivolumab is an antibody (a type of human protein) that is being tested to see if it will allow the bodys immune system to work against tumor cells. The effectiveness of BMS-936558…
Condition: Cancer / Lung Cancer
Investigator: Teri Kreisl, MD
Status: Closed
The purpose of this study is to obtain information on the safety and effectiveness of NovoTTF-100M (study device) in subjects with brain metastases (tumors) as a result of non-small cell lung cancer (NSCLC).
Condition: Neurological Disorders / Brain Tumors
Investigator: Mary Welch, MD
Status: Closed
The purpose of this clinical study is to evaluate safety of the study treatment, its effects on the immune system and on GBM. The study treatment includes several experimental therapies: INO-5401 + INO-9012 delivered by an electroporation device called CELLECTRA 2000 used for delivery of INO-5401 + INO-9012 into your muscle. You will also receive another…